Waycross Partners’s Edwards Lifesciences EW Stock Holding History

Waycross Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-187,562	Closed	-$12.4M	–	65
2024 Q3	$12.4M	Buy	187,562 +20,796	+12%	+$1.51M	1.71%	27
2024 Q2	$15.4M	Buy	166,766 +32,296	+24%	+$2.86M	2.36%	15
2024 Q1	$12.8M	Buy	134,470 +11,149	+9%	+$937K	2.21%	21
2023 Q4	$9.4M	Sell	123,321 -7,447	-6%	-$518K	1.76%	26
2023 Q3	$9.06M	Buy	130,768 +6,833	+6%	+$549K	2%	24
2023 Q2	$11.7M	Buy	123,935 +27,144	+28%	+$2.36M	2.54%	14
2023 Q1	$8.01M	Buy	96,791 +17,035	+21%	+$1.34M	2.33%	18
2022 Q4	$5.95M	Buy	+79,756	New	+$6.15M	2.16%	18
2021 Q3	–	Sell	-35,366	Closed	-$3.66M	–	90
2021 Q2	$3.66M	Sell	35,366 -1,785	-5%	-$168K	1.95%	20
2021 Q1	$3.11M	Sell	37,151 -3,659	-9%	-$309K	1.73%	19
2020 Q4	$3.72M	Buy	+40,810	New	+$3.39M	2.32%	15

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Waycross Partners's EW Position: Q4 2024 in Review

Waycross Partners sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 187,562 shares — an estimated $12.4M sold.

Waycross Partners first reported a position in EW in Q4 2020 and held it in 11 quarters. The position peaked at $15.4M in Q2 2024. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2024.

Waycross Partners reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
Waycross Partners sold 187,562 Edwards Lifesciences shares in Q4 2024, an estimated $12.4M.
Waycross Partners first reported a position in Edwards Lifesciences in Q4 2020 and held it in 11 quarters.
Waycross Partners's Edwards Lifesciences position peaked at $15.4M in Q2 2024.
1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on Waycross Partners's 13F filing for Q4 2024, filed 31 Jan 2025.